Skip to main content
ADAG
NASDAQ Life Sciences

Adagene Secures NMPA Clearance to Launch Phase 1 Trial for ADG138, a Double-Masked HER2xCD3 T-Cell Engager

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.21
Mkt Cap
$215.53M
52W Low
$1.3
52W High
$4.85
52W Position info
147% above low
Off High info
34% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ADAG has more than doubled off its 52-week low of $1.3 on light trading volume (0.3× avg).

Summary

Adagene received NMPA clearance to begin a Phase 1 trial for ADG138, a double-masked HER2xCD3 T-cell engager, with dosing expected to start in China in Q4 2026.


Key Events · Product Development and Regulatory · ADAG

  • NMPA Clears IND for ADG138

    China's NMPA approved Adagene's investigational new drug application for ADG138, a double-masked HER2xCD3 bispecific T-cell engager built on the SAFEbody platform.

  • Phase 1 Trial to Start Q4 2026

    Adagene expects to initiate a first-in-human Phase 1 study of ADG138 in patients with advanced solid tumors in China in the fourth quarter of 2026.

  • Preclinical Differentiation

    ADG138 showed tumor regression in HER2-high and HER2-low models, including Enhertu-resistant tumors, and synergy with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies.

  • Pipeline Expansion Beyond Muzastotug

    This is Adagene's second clinical-stage program, broadening the pipeline beyond lead asset muzastotug (ADG126) and demonstrating the SAFEbody platform's applicability to T-cell engagers.


Analysis · ADAG · Life Sciences

China's NMPA has cleared Adagene's IND for ADG138, a novel double-masked bispecific T-cell engager targeting HER2 and CD3. This milestone expands the company's clinical pipeline beyond its lead asset muzastotug and validates the SAFEbody platform in a second modality. A first-in-human Phase 1 study in advanced solid tumors is expected to begin in Q4 2026. Preclinical data demonstrated tumor regression in Enhertu-resistant models and synergy with checkpoint inhibitors, suggesting a differentiated profile for HER2-expressing cancers.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADAG was trading at $3.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $215.5M. The 52-week trading range was $1.30 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADAG - Latest Insights

ADAG
Nov 09, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.63 info
Change: -$0.370 (-19%) info
Market Cap: $114.815M info
ADAG
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.63 info
Change: -$0.370 (-19%) info
Market Cap: $114.815M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $1.63 info
Change: -$1.58 (-49%) info
Market Cap: $114.815M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $1.63 info
Change: -$2.17 (-57%) info
Market Cap: $114.815M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $1.63 info
Change: -$2.17 (-57%) info
Market Cap: $114.815M info